Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment guidelines news

Show

From To
Zimbabwe finally switches away from stavudine

The Zimbabwean government has finally dropped stavudine, lamivudine and nevirapine as its first-line HIV therapy in favour of a single dose treatment which has a combination of three drugs, namely tenofovir/lamivudine/efavirenz (TLN).The Government dropped the first line HIV treatment after realizing that it was causing severe side effects on patients. Stanley Takaona of the Zimbabwe HIV and AIDS Activist Union Community Trust said the introduction of the new HIV drug was going to save more lives.

Published
19 January 2015
From
AllAfrica
Dolutegravir and Truimeq approved in England: London guidelines updated

On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

Published
14 January 2015
From
HIV i-Base
Study uncovers new ground about when to start HIV therapy

A major question that has recurred since the availability of potent combination anti-HIV therapy (commonly called ART or HAART) is when this therapy should be initiated to ensure the optimal health of HIV-positive people. New research has revealed that early therapy may be highly beneficial.

Published
13 January 2015
From
CATIE
Dolutegravir/abacavir/lamivudine: considerable added benefit for treatment-naive adults with HIV

Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. The Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.

Published
12 January 2015
From
The Institute for Quality and Efficiency in Health Care
First Year After HIV Infection Is Key Window for Treatment Start

Waiting to start HIV treatment until 12 months after the estimated date of seroconversion decreases the likelihood of restoring the immune system.

Published
07 January 2015
From
AIDSMeds
Zimbabwe: Govt introduces new HIV treatment

The Zimbabwean government is with effect from this month switching all people on HIV treatment to a new one of one tablet per day from the previous three pills to make it easier for patients not to default on taking medication. The new single tablet has a combination of three drugs (Tenofovir/Lamivudine/Efavirenz TLE), a departure from the previous complicated treatment of three different tablets namely Tenofovir, Lovovidine and Nevirapine (TLN).

Published
07 January 2015
From
NewZimbabwe.com
US guidelines on prevention with people living with HIV now emphasise engagement with care, HIV treatment and social factors

The American public health agency, the Centers for Disease Control and Prevention (CDC) has published new recommendations on the HIV prevention interventions and advice that should

Published
05 January 2015
By
Roger Pebody
Starting HIV Meds Within a Year of Infection Helps Restore CD4s

Beginning treatment for HIV within a year of infection improves the likelihood of returning an individual’s CD4 count to a normal level.

Published
03 December 2014
From
AIDSMeds
WHO: Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children

Recommendations for a public health approach - December 2014 supplement to the 2013 consolidated ARV guidelines.

Published
02 December 2014
From
World Health Organization
START Study Could Change How We Look at HIV Treatment, and HIV Itself

Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.

Published
25 November 2014
From
The Body
← First12345...25Next →

Filter by country